Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Single or Dual Antiplatelet Therapy in Stroke or Transient Ischemic Attack?

Antiplatelet therapy is key to prevent thrombotic events after a transient ischemic attack (TIA) or ischemic stroke. The role of aspirin is well established in this scenario, but there is emerging evidence for a short period of dual antiplatelet therapy (DAPT). Now, can this strategy avoid recurrent strokes without paying a price in terms of bleeding?

Antiagregación plaquetaria en el stroke o TIA

To answer this question, authors conducted a meta-analysis, published in STROKE, including all randomized studies comparing early start of short-term of dual antiplatelet therapy (up to 3 months) with aspirin plus a P2Y12 receptor inhibitor vs. aspirin alone in patients with stroke or transient ischemic attack.

The primary endpoint was risk of recurrent stroke, and the primary safety endpoint was major bleeding. Secondary endpoints included any stroke, hemorrhagic stroke, major cardiovascular event, and all-cause death.

Four large trials with a total of over 20,000 patients were included.

Dual antiplatelet therapy significantly lowered the risk of recurrent stroke (risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.68-0.83; p < 0.001). Its price? The rates for major bleeding doubled (RR: 2.22; 95% CI: 1.14–4.34; p = 0.02).


Read also: Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.


Patients receiving DAPT also had a significantly lower risk of cardiovascular events (RR: 0.76; 95% CI: 0.69–0.84; p < 0.001), and of recurrent ischemic events (RR: 0.74; 95% CI: 0.67–0.82; p < 0.001).

Conclusion

Dual antiplatelet therapy for no more than 3 months prescribed within 24 hours of a high-risk transient ischemic attack or a mild to moderate stroke significantly lowers the risk of recurrent strokes compared with aspirin alone. The cost is a significant increase in major bleeding.

We need more evidence to adequately select which patients may derive a benefit.

Título original: Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack. Meta-Analysis of Randomized Controlled Trials.

Referencia: Kirtipal Bhatia et al. Stroke. 2021 Apr 27;STROKEAHA120033033. doi: 10.1161/STROKEAHA.120.033033.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...